From: Factors associated with engraftment success of patient-derived xenografts of breast cancer
All (n = 320) | Univariate ** (Odds ratio, 95% CI, p-value***) | Multivariate ** (Odds ratio, 95% CI, p-value***) | NAC group (n = 131) | Univariate ** (Odds ratio, 95% CI, p-value***) | Multivariate** (Odds ratio, 95% CI, p-value***) | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Variable* | Failure (n = 270) | Success (n = 50) | Variable* | Failure (n = 93) | Success (n = 38) | ||||||
AP | Mean ± SD | 639.9 ± 727.1 | 409.0 ± 484.0 | 0.61 (0.47–0.79, p = 0.035) | AP | Mean ± SD | 517.3 ± 622.2 | 450.9 ± 528.0 | 0.82 (0.74–0.91, p = 0.562) | ||
NP | Mean ± SD | 740.7 ± 981.9 | 1575.0 ± 1264.1 | 1.58 (1.39–1.80, p < 0.001) | 1.927 (1.077–3.449, p = 0.027) | NP | Mean ± SD | 901.3 ± 1101.4 | 1642.8 ± 1358.9 | 1.60 (1.38–1.85, p = 0.003) | |
TDLUP | Mean ± SD | 504.4 ± 692.5 | 219.8 ± 233.3 | 0.18 (0.08–0.41, p = 0.006) | TDLUP | Mean ± SD | 475.2 ± 730.2 | 201.6 ± 213.9 | 0.22 (0.18–0.27, p = 0.034) | 0.181 (0.033–1.00, p = 0.06) | |
SP | Mean ± SD | 3377.5 ± 1265.9 | 2855.3 ± 1094.8 | 0.63 (0.46–0.86, p = 0.007) | 1.545 (0.844–2.827, p = 0.159) | SP | Mean ± SD | 3512.4 ± 1523.4 | 2855.7 ± 1180.3 | 0.71 (0.60–0.84, p = 0.022) | |
TILP | Mean ± SD | 17.8 ± 22.8 | 15.0 ± 15.9 | 0.00 (0–7833.4, p = 0.401) | TILP | Mean ± SD | 10.2 ± 14.0 | 11.3 ± 13.3 | 283.00 (29.48–2718.95, p = 0.676) | ||
ICP | Mean ± SD | 4208.0 ± 1450.8 | 4571.6 ± 1201.5 | 1.19 (0.97–1.45, p = 0.097) | 1.820 (1.028–3.223, p = 0.040) | ICP | Mean ± SD | 4105.8 ± 1552.8 | 4505.6 ± 1187.3 | 1.00 (1.00–1.00, p = 0.159) | |
Age | Mean ± SD | 50.9 ± 12.1 | 45.6 ± 10.4 | 0.96 (0.94–0.99, p = 0.005) | 0.96 (0.92–1.00, p = 0.032) | Age | Mean ± SD | 49.6 ± 10.3 | 45.6 ± 11.0 | 0.96 (0.93–1.00, p = 0.053) | |
Ki-67LI (%) | Mean ± SD | 41.2 ± 28.7 | 74.0 ± 14.3 | 1.06 (1.04–1.08, p < 0.001) | 1.05 (1.02–1.07, p < 0.001) | Ki-67LI (%) | Mean ± SD | 39.2 ± 32.5 | 75.0 ± 14.3 | 1.06 (1.03–1.09, p < 0.001) | 1.07 (1.03–1.10, p < 0.001) |
Subtype | HER2 + | 20 (7.4%) | 1 (2%) | Subtype | HER2 + | 8 (8.6%) | 1 (2.6%) | ||||
HR + | 130 (48.1%) | 4 (8%) | 0.62 (0.07–5.79, p = 0.671) | HR + | 35 (37.6%) | 3 (7.9%) | 0.69 (0.06–7.48, p = 0.757) | ||||
HR + /HER2 + | 30 (11.1%) | 1 (2%) | 0.67 (0.04–11.29, p = 0.779) | HR + /HER2 + | 14 (15.1%) | 1 (2.6%) | 0.57 (0.03–10.43, p = 0.706) | ||||
TNBC | 90 (33.3%) | 44 (88%) | 9.78 (1.27–75.23, p = 0.028) | TNBC | 36 (38.7%) | 33 (86.8%) | 7.33 (0.87–61.82, p = 0.067) | ||||
Diagnosis | IDC | 250 (92.6%) | 45 (90%) | Diagnosis | IDC | 87 (93.5%) | 34 (89.5%) | ||||
Other | 20 (7.4%) | 5 (10%) | 1.39 (0.50–3.89, p = 0.532) | Other | 6 (6.5%) | 4 (10.5%) | 1.71 (0.45–6.42, p = 0.430) | ||||
HG | 2 | 139 (51.5%) | 3 (6%) | HG | 2 | 41 (44.1%) | 3 (7.9%) | ||||
3 | 131 (48.5%) | 47 (94%) | 16.62 (5.05–54.71, p < 0.001) | 4.34 (1.08–17.53, p = 0.039) | 3 | 52 (55.9%) | 35 (92.1%) | 9.20 (2.64–32.05, p < 0.001) | |||
NAC | No | 177 (65.6%) | 12 (24%) | Miller-Payne grade | Mean ± SD | 2.3 ± 0.8 | 1.6 ± 0.8 | 0.34 (0.20–0.57, p < 0.001) | 0.30 (0.16–0.58, p < 0.001) | ||
Yes | 93 (34.4%) | 38 (76%) | 6.03 (3.01–12.09, p < 0.001) | 3.27 (1.41–7.60, p = 0.006) | RCB score | Mean ± SD | 3.1 ± 1.0 | 3.4 ± 1.2 | 1.24 (0.86–1.78, p = 0.253) | ||
Size (cm) | Mean ± SD | 3.1 ± 2.0 | 4.4 ± 2.8 | 1.23 (1.09–1.38, p < 0.001) | 1.20 (1.02–1.41, p = 0.029) | Size (cm) | Mean ± SD | 4.0 ± 2.6 | 5.0 ± 2.9 | 1.13 (0.99–1.30, p = 0.064) | |
LVI | No | 151 (55.9%) | 30 (60%) | LVI | No | 44 (47.3%) | 21 (55.3%) | ||||
Yes | 119 (44.1%) | 20 (40%) | 0.85 (0.46–1.56, p = 0.594) | Yes | 49 (52.7%) | 17 (44.7%) | 0.73 (0.34–1.55, p = 0.410) | ||||
Metastatic LNs | Mean ± SD | 2.1 ± 5.8 | 4.5 ± 9.5 | 1.04 (1.00–1.08, p = 0.031) | Metastatic LNs | Mean ± SD | 4.1 ± 8.9 | 5.8 ± 10.6 | 1.02 (0.98–1.06, p = 0.350) | ||
TIL (%) | Mean ± SD | 12.0 ± 18.4 | 9.4 ± 13.8 | 0.99 (0.97–1.01, p = 0.351) | TIL (%) | Mean ± SD | 6.1 ± 11.6 | 6.3 ± 8.5 | 1.00 (0.97–1.04, p = 0.928) |